| ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity MC Poffenberger, JL Bishop, RJ Blackler, KG Haworth, S Booth, ... Cancer Research 83 (7_Supplement), 2935-2935, 2023 | | 2023 |
| Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use A Zoubeidi, RSN Munuganti, JL Bishop, D Thaper, S Vahid US Patent App. 17/282,319, 2022 | | 2022 |
| An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ... Nature cell biology 23 (9), 1023-1034, 2021 | 92 | 2021 |
| Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation JL Bishop, R Blackler, G Volkers, M Poffenberger, I Yu, J Smith, ... Cancer Research 81 (13_Supplement), 1788-1788, 2021 | 4 | 2021 |
| The Financial Impact of Immune Effector Cell Therapy on the Care of Patients with Advanced, B Cell Malignancies RT Maziarz, P Appel, B Cota, J Bishop 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021 | | 2021 |
| PEG10 is associated with treatment-induced neuroendocrine prostate cancer S Kim, D Thaper, S Bidnur, P Toren, S Akamatsu, JL Bishop, C Colins, ... Journal of Molecular Endocrinology 63 (1), 39-49, 2019 | 30 | 2019 |
| Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer D Thaper, S Vahid, R Kaur, S Kumar, S Nouruzi, JL Bishop, M Johansson, ... Scientific reports 8 (1), 17307, 2018 | 34 | 2018 |
| Abstract A033: Identity fraud: Lineage plasticity as a mechanism of antiandrogen resistance and target for therapy A Davies, C Bostock, M Ahmed, YY Lin, F Johnson, KM Nip, K Ketola, ... Cancer Research 78 (16_Supplement), A033-A033, 2018 | | 2018 |
| Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy AH Davies, C Bostock, M Ahmed, YY Lin, F Johnson, KM Nip, K Ketola, ... Cancer Research 78 (13_Supplement), 4995-4995, 2018 | | 2018 |
| Targeting master neuronal transcription factor BRN2 in neuroendocrine prostate cancer D Thaper, R Munuganti, S Norouzi, S Kumar, S Kim, K Singh, S Vahid, ... Cancer Research 78 (13_Supplement), 1931-1931, 2018 | | 2018 |
| Castration-Resistant Prostate Cancer AH Davies, JL Bishop, A Zoubeidi Precision Molecular Pathology of Prostate Cancer, 297-322, 2018 | 2 | 2018 |
| Targeting prostate cancer subtype 1 by forkhead box M1 pathway inhibition K Ketola, RSN Munuganti, A Davies, KM Nip, JL Bishop, A Zoubeidi Clinical Cancer Research 23 (22), 6923-6933, 2017 | 38 | 2017 |
| EZH2 reprogramming confers intrinsic stem cell properties and developmental plasticity driving neuroendocrine prostate cancer A Davies, M Ahmed, C Bostock, A Gleave, K Ketola, F Johnson, J Bishop, ... Cancer Research 77 (13_Supplement), 5025-5025, 2017 | | 2017 |
| Neuronal transcription factor BRN2 is an androgen suppressed driver of neuroendocrine differentiation in prostate cancer JL Bishop, D Thaper, S Vahid, RS Munuganti, P Ahn, A Davies, K Ketola, ... Cancer Research 77 (13_Supplement), 3189-3189, 2017 | | 2017 |
| Targeting Lyn regulates Snail family shuttling and inhibits metastasis D Thaper, S Vahid, KM Nip, I Moskalev, X Shan, S Frees, ME Roberts, ... Oncogene 36 (28), 3964-3975, 2017 | 38 | 2017 |
| Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance M Nouri, J Caradec, AA Lubik, N Li, BG Hollier, M Takhar, ... Oncotarget 8 (12), 18949, 2017 | 74 | 2017 |
| Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis B Benzon, SG Zhao, MC Haffner, M Takhar, N Erho, K Yousefi, P Hurley, ... Prostate cancer and prostatic diseases 20 (1), 28-35, 2017 | 145 | 2017 |
| Immuno-oncology of Dormant Tumours N Nabavi, ME Roberts, F Crea, CC Collins, Y Wang, JL Bishop Tumor Dormancy and Recurrence, 51-60, 2017 | 2 | 2017 |
| The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... Cancer discovery 7 (1), 54-71, 2017 | 358 | 2017 |
| Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer S Vahid, D Thaper, KF Gibson, JL Bishop, A Zoubeidi Scientific reports 6 (1), 31842, 2016 | 58 | 2016 |
